This page was written by Patron Accounting’s AI from the official release and reviewed before publishing. It explains the document in plain language. It is not the document itself. Where this page and the original differ, the original governs.
The short version
- The company asked whether its clinical trial services for foreign sponsors were GST exports.
- The authority said no, because the sponsor's drug is consumed in the study.
- The place of supply rule for goods made available by the recipient decided the case.
- The services are taxed under CGST and SGST, not as zero-rated exports.
- The ruling binds only the company that asked and its own tax office.
In short
Cliantha Research Limited, a clinical research company in Maharashtra, asked the GST advance ruling authority whether its trials on drugs supplied by foreign sponsors could be treated as exports. The company runs bioequivalence studies on volunteers using tablets, capsules and syrups that the sponsor supplies, consumes during the study, and does not take back. It delivers a digital report to the sponsor and is paid in foreign currency.
What has changed
How it worked before
Many clinical research providers had relied on earlier Tribunal decisions, including Advinus, Sai Life and B.A. Research, to treat such work as exports. Those decisions were given under earlier law, so their effect under GST was not settled.
What has changed
The authority held that the work is not an export of services. Where the recipient must make goods physically available to the supplier, the place of supply is where the service is performed. The sponsor's investigational product falls in that category, and the law has no exception for goods consumed during the study. So the work is taxed as a supply within Maharashtra, under CGST and SGST. The authority also noted that the company had itself charged 18% IGST on its invoices. The ruling does not decide the correct rate or classification.
Who this affects
Clinical research organisations, bioequivalence and bioavailability testing centres, and clinical trial sites in India that test drugs supplied by overseas sponsors.
An example
A testing centre in Pune runs a bioequivalence study for a German drug company. The German sponsor ships tablets to the centre, which gives them to volunteers, and the centre emails the analysis report and is paid in euros. The centre would ask whether it can zero-rate the invoice as an export. This ruling suggests it cannot, because the tablets are goods the sponsor made available and the centre consumed in the study, so the place of supply is Pune and CGST and SGST apply.
What you should do
Do not treat this ruling as law for your business, because an advance ruling binds only the company that asked and its own tax office. Check whether your sponsor or client supplies physical goods that you use and consume in the work. If it does, the reasoning is likely to apply to you, so review your invoicing with your tax adviser before zero-rating any supply as an export. If your work is done remotely or no goods are supplied, this ruling does not answer your question.
If you do nothing
If you assume the work is an export and do not charge tax, a tax officer may treat the supply as taxable and demand the unpaid tax. That demand can carry interest and penalty. Because the company in this case had charged IGST and still lost the export argument, a mismatch between your invoices and your position can also draw attention.
The terms explained
- advance ruling
- A decision by a GST authority on a specific business's question before the business acts. It binds only that business and its own tax office.
- export of services
- A service supplied from India to a recipient outside India that meets the conditions in the law, which can allow it to be taxed at zero rate.
- place of supply
- The rule that decides which state or country a service is treated as supplied in. That answer decides whether the tax is IGST or CGST and SGST.
- bioequivalence study
- A clinical test on volunteers that checks whether a generic medicine works in the body the same way as the original medicine.
- investigational product
- A drug or medicine being tested in a clinical trial, which the sponsor supplies to the testing site.
The ruling in detail
Authority for Advance Ruling
Cliantha Research Limited
NO.GST-ARA-119/2018-19/B-50, Mumbai, dt. 04/05/2019 · Maharashtra
Questions before the authority
- Whether the clinical research services proposed to be provided by the applicant to entities located outside India are liable to CGST, SGST or IGST, or are eligible to be treated as an export of service under Section 2(6) of the IGST Act, 2017.
Facts
The applicant is a clinical research organisation in India that conducts bioequivalence and bioavailability studies on human volunteers using investigational products (tablets, capsules, syrups and similar forms) supplied by foreign sponsors. The sponsor's product is consumed during the study and is not returned, and the applicant delivers a digital analysis report to the sponsor. The applicant raises invoices in foreign currency and receives payment in foreign currency.
Ruling
| Question | What the authority ruled |
|---|---|
| Whether clinical research services to foreign sponsors are an export of service under s.2(6) IGST Act 2017 | **Not eligible** to be treated as export of service; liable to CGST and SGST The order rests on place of supply under s.13(3)(a) IGST Act, the place of performance being in the same State as the supplier. Other s.2(6) conditions were accepted as met; the place-of-supply condition was not. |
The authority held that the services are not eligible to be treated as an export of service under Section 2(6) of the IGST Act, 2017. The services are liable to CGST and SGST because the place of supply under Section 13(3)(a) of the IGST Act is the location where the services are performed, which is the same State as the supplier.
Reasoning
The authority accepted that the applicant's transaction satisfied conditions (i), (ii), (iv) and (v) of Section 2(6) but held that condition (iii), that the place of supply be outside India, was not met. Section 13(2) would ordinarily place supply at the recipient's location, but Section 13(3)(a) applies where the services are in respect of goods required to be made physically available by the recipient to the supplier. The authority found that the sponsor's investigational product falls within this category and that the clause contains no exception for goods consumed during the study. It also rejected the applicant's reliance on the Tribunal decisions in Advinus, Sai Life and B.A. Research, noting that they were decided under the pre-GST or Rule 4 of the Place of Provision of Services Rules, 2012 regime, and observed that the applicant had itself charged 18% IGST on invoices.
Provisions relied on
- Section 2(6) of the IGST Act, 2017 (definition of export of services)
- Section 13(2) of the IGST Act, 2017 (default place of supply)
- Section 13(3)(a) of the IGST Act, 2017 (services in respect of goods made physically available by the recipient)
- Rule 4 of the Place of Provision of Services Rules, 2012 (cited by the applicant)
- Section 8, Explanation 1 (referred to in s.2(6)(v))
For the practitioner
This order is useful for testing and clinical research providers in India who work on sponsor-supplied drugs consumed during the study. It indicates that the Section 13(3)(a) goods-based place-of-supply rule will likely displace the export argument even where the report is delivered abroad and paid for in foreign currency. The order binds only the applicant and does not decide cases where the recipient supplies no goods, where the work is performed remotely, or the classification and rate issues. Those points would need separate analysis.
Source
This is a summary prepared from the published order, which is a scanned document. It is a reading aid and not the authority: where the two differ, the order governs. Verify every provision against the original before relying on it.
Original order: https://www.gstcouncil.gov.in/sites/default/files/AAR/maharashtra_aar_119_2018-19_crl_04.05.19.pdf
Legibility of the scan, as read: high.
Prepared 03-11-2026.
About Patron Accounting LLP
Patron Accounting LLP is a CA and CS-led accounting and compliance firm that has been working with businesses across India since 2019. We handle the work that keeps a company correct with every department it answers to: day-to-day bookkeeping and accounting, GST registration and returns, income tax filing and assessments, TDS, payroll and PF/ESI, company and LLP incorporation, ROC and MCA compliance, statutory and internal audit, physical stock and inventory audits, trademark and other registrations, and the certificates and reports that banks, buyers and regulators ask for.
Our clients range from a first proprietorship registering for GST to established companies running operations across several states. Much of our work is exactly this: reading what a department has published and telling a business, in plain terms, whether it changes anything for them.
We operate from five offices and serve clients across the rest of India remotely:
- Pune (HQ): RTC Silver, B4-708, Sai Satyam Park, Wagholi, Pune, Maharashtra 412207
- Mumbai: 1st Floor, Rajshila Building, 104/597, Jagannath Shankar Seth Rd, Marine Lines, Mumbai 400002
- Delhi: First Floor, Plot No. C-134-A, A-1 Block, Qutub Vihar Phase-1, New Delhi 110071
- Gurugram: 705, 7th Floor, ILD Trade Centre, Sohna Road, Sector 47, Gurugram 122018
- Ahmedabad: Phoenix Tower, 1107, near Commerce Six Road, Drive In Road, Navrangpura, Ahmedabad, Gujarat 380009
If anything on this page affects you and you would like somebody to look at your own position, we are glad to help. Call +91 94594 56700, write to sales@patronaccounting.com, or visit patronaccounting.com. The first conversation costs nothing.
